Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE)
· seekingalpha.com
Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.
Pfizer ( PFE ) is a good medium- to long-term investment despite near-term challenges from COVID revenue normalization and looming patent expiry over the coming...